Services

Active in follow-on biologics since 2009, we bring international expertise in four areas

Expert review, opinion, and litigation support of follow-on biologics

  • Expert analysis, evidence, and testimony of biosimilars and other follow-on biologics
  • Statistical modeling of therapeutic interchangeability of reference and follow-on biologics
  • Risk analysis of conversion to and utilization of biosimilars and other follow-on biologics
  • Scientific review, due diligence, and validation of follow-on biologics
  • Knowledge and data synthesis of follow-on biologics

Value, economics, and equity of follow-on biologics

  • Economic modeling and value appraisal of follow-on biologics
  • Comparative cost-efficiency and expanded access analysis of follow-on biologics
  • Comparative budget impact and affordability analysis of reference and follow-on biologics
  • Alternate and novel metrics of benefit and harm of follow-on biologics
  • Shadow modeling of health technology assessment and formulary appraisals of follow-on biologics
  • Market access strategy of follow-on biologics
  • Virtual health economics services targeting follow-on biologics

Real-world clinical evidence of follow-on biologics

  • Scientific strategy, portfolio management, and lifecycle integration of follow-on biologics
  • Scientific and technical review, due diligence, and validation of follow-on biologics
  • Advanced modeling and analytics specific to follow-on biologics
  • Scientific and professional communication in the follow-on biologics space
  • Virtual health outcomes research services focused on follow-on biologics

Evidence-based translation of follow-on biologics

  • Evidence synthesis, translation, and application of follow-on biologics
  • Systematic reviews and meta-analyses of reference and follow-on biologics
  • Comparative clinical risk analysis of reference and follow-on biologics

Thought Leadership and Publications ->